Our top pick for
RTI Surgical Holdings Inc is a medical devices business based in the US. RTI Surgical shares (RTIX) are listed on the NASDAQ and all prices are listed in US Dollars. RTI Surgical employs 935 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$1.70 - $2.78|
|50-day moving average||$2.25|
|200-day moving average||$2.29|
|Wall St. target price||$5.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.05|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing RTI Surgical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of RTI Surgical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
RTI Surgical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.39. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into RTI Surgical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
RTI Surgical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.7 million.
The EBITDA is a measure of a RTI Surgical's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$284.8 million|
|Gross profit TTM||$174.7 million|
|Return on assets TTM||-3.42%|
|Return on equity TTM||0%|
|Market capitalisation||$234.2 million|
TTM: trailing 12 months
There are currently 1.3 million RTI Surgical shares held short by investors – that's known as RTI Surgical's "short interest". This figure is 39.5% up from 966,456 last month.
There are a few different ways that this level of interest in shorting RTI Surgical shares can be evaluated.
RTI Surgical's "short interest ratio" (SIR) is the quantity of RTI Surgical shares currently shorted divided by the average quantity of RTI Surgical shares traded daily (recently around 532778.26086957). RTI Surgical's SIR currently stands at 2.53. In other words for every 100,000 RTI Surgical shares traded daily on the market, roughly 2530 shares are currently held short.
However RTI Surgical's short interest can also be evaluated against the total number of RTI Surgical shares, or, against the total number of tradable RTI Surgical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case RTI Surgical's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 RTI Surgical shares in existence, roughly 20 shares are currently held short) or 0.0188% of the tradable shares (for every 100,000 tradable RTI Surgical shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against RTI Surgical.
Find out more about how you can short RTI Surgical stock.
We're not expecting RTI Surgical to pay a dividend over the next 12 months.
Over the last 12 months, RTI Surgical's shares have ranged in value from as little as $1.7 up to $2.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while RTI Surgical's is 2.0319. This would suggest that RTI Surgical's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Surgalign Holdings, Inc. , a medical technology company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It offers coflex interlaminar stabilization device, an implant for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; SImmetry sacroiliac joint fusion system, which decreases in opioid use, pain, and disability; and Fortilink IBF system with TETRAfuse ?3D technology. The company's implants are used in the fields of orthopedic, spine, sports medicine, plastic surgery, trauma, and other surgical procedures to repair and promote the natural healing of human bone and other human tissues; and to enhance surgical outcomes. It markets its products through its direct distribution force and various OEM relationships to healthcare providers, hospitals, and other healthcare facilities, as well as through a network of independent distributors. The company was founded in 1997 and is headquartered in Deerfield, Illinois. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.